Fda: approves blujepa for uncomplicated urogenital gonorrhea in some adult & pediatric patients 12 years of age & older - website
Published on 12/11/2025 at 12:30 pm EST

|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,816.00 GBX | -0.03% |
|
-3.25% | -0.47% |
| Jan. 16 | Where the Money's Moving | |
| Jan. 16 | Some drugmakers quietly concerned about legal risk with speedy FDA review program | RE |
Published on 12/11/2025 at 12:30 pm EST

Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

Select your edition
All financial news and data tailored to specific country editions